The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies.

The American Cancer Society estimates nearly 21,000 new cases of ovarian cancer will be diagnosed in the United States this year, with 60 ...

Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian, endometrial, and cervical cancers.

The real-world benefit of adding bevacizumab to a first-line chemotherapy regimen for patients with epithelial ovarian cancer was limited to those with high-risk prognostic factors, according to a ...